.png)
.png)
Target proteins can have different roles in diseased and healthy cells. Conventional approaches risk harming beneficial functions while blocking harmful ones. Protai’s AIMS™ platform maps cell type protein states to define a precise, context-specific mechanism-of-action. This allows selective inhibition of disease-relevant activity while preserving beneficial functions, leading to smarter targeting and better outcomes.
AIMS™ utilizes structural proteomics (XL-MS, HDX-MS) to determine the disease-specific protein state conformation. The conformation is then modeled using structural AI and simulations to pinpoint pockets that achieve the desired mechanism-of-action.
Enables discovery of modulators for redefined targets in cancer and autoimmune diseases.
Get in touch with us for questions and potential collaborations.
